{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,15]],"date-time":"2026-09-15T18:05:44Z","timestamp":1789495544693,"version":"build-2803163510"},"reference-count":39,"publisher":"Japan Endocrine Society","issue":"5","funder":[{"DOI":"10.13039\/501100012036","name":"Lotte Foundation","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100012036","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001691","name":"Japan Society for the Promotion of Science","doi-asserted-by":"publisher","award":["23K08006"],"award-info":[{"award-number":["23K08006"]}],"id":[{"id":"10.13039\/501100001691","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100016573","name":"Japan Association for Diabetes Education and Care","doi-asserted-by":"publisher","award":["2024-MED-003"],"award-info":[{"award-number":["2024-MED-003"]}],"id":[{"id":"10.13039\/100016573","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100007664","name":"Manpei Suzuki Diabetes Foundation","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100007664","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Endocr J"],"published-print":{"date-parts":[[2026]]},"DOI":"10.1507\/endocrj.ej25-0402","type":"journal-article","created":{"date-parts":[[2026,1,28]],"date-time":"2026-01-28T22:08:31Z","timestamp":1769638111000},"page":"607-619","source":"Crossref","is-referenced-by-count":4,"title":["Effects of semaglutide, a GLP-1 receptor agonist, on food preferences in Japanese subjects with type 2 diabetes and visceral fat accumulation"],"prefix":"10.1507","volume":"73","author":[{"given":"Tomoyuki","family":"Hara","sequence":"first","affiliation":[{"name":"Department of Metabolic Medicine, Graduate School of Medicine, The University of Osaka, Osaka 565-0871, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0028-1757","authenticated-orcid":false,"given":"Yuya","family":"Fujishima","sequence":"additional","affiliation":[{"name":"Department of Metabolic Medicine, Graduate School of Medicine, The University of Osaka, Osaka 565-0871, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yu","family":"Kimura","sequence":"additional","affiliation":[{"name":"Department of Metabolic Medicine, Graduate School of Medicine, The University of Osaka, Osaka 565-0871, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kohei","family":"Fujii","sequence":"additional","affiliation":[{"name":"Department of Metabolic Medicine, Graduate School of Medicine, The University of Osaka, Osaka 565-0871, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yusuke","family":"Kawachi","sequence":"additional","affiliation":[{"name":"Department of Diabetes Endocrinology, Rinku General Medical Center, Osaka 598-0048, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0001-1261-4160","authenticated-orcid":false,"given":"Hirofumi","family":"Nagao","sequence":"additional","affiliation":[{"name":"Department of Metabolic Medicine, Graduate School of Medicine, The University of Osaka, Osaka 565-0871, Japan"},{"name":"Department of Metabolism and Atherosclerosis, Graduate School of Medicine, The University of Osaka, Osaka 565-0871, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3443-3635","authenticated-orcid":false,"given":"Yoshinari","family":"Obata","sequence":"additional","affiliation":[{"name":"Department of Metabolic Medicine, Graduate School of Medicine, The University of Osaka, Osaka 565-0871, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0712-7154","authenticated-orcid":false,"given":"Shiro","family":"Fukuda","sequence":"additional","affiliation":[{"name":"Department of Metabolic Medicine, Graduate School of Medicine, The University of Osaka, Osaka 565-0871, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Naoko","family":"Nagai","sequence":"additional","affiliation":[{"name":"Department of Metabolic Medicine, Graduate School of Medicine, The University of Osaka, Osaka 565-0871, Japan"},{"name":"Division of Nutrition Management, The University of Osaka Hospital, Osaka 565-0871, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7845-9693","authenticated-orcid":false,"given":"Hitoshi","family":"Nishizawa","sequence":"additional","affiliation":[{"name":"Department of Metabolic Medicine, Graduate School of Medicine, The University of Osaka, Osaka 565-0871, Japan"},{"name":"Department of Metabolism and Atherosclerosis, Graduate School of Medicine, The University of Osaka, Osaka 565-0871, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0851-9603","authenticated-orcid":false,"given":"Iichiro","family":"Shimomura","sequence":"additional","affiliation":[{"name":"Department of Metabolic Medicine, Graduate School of Medicine, The University of Osaka, Osaka 565-0871, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"386","reference":[{"key":"1","doi-asserted-by":"crossref","unstructured":"1 Bl\u00fcher M (2019) Obesity: global epidemiology and pathogenesis. Nat Rev Endocrinol 15: 288\u2013298.","DOI":"10.1038\/s41574-019-0176-8"},{"key":"2","doi-asserted-by":"crossref","unstructured":"2 Miyazawa I, Kadota A, Miura K, Okamoto M, Nakamura T, et al. (2018) Twelve-year trends of increasing overweight and obesity in patients with diabetes: the Shiga Diabetes Clinical Survey. Endocr J 65: 527\u2013536.","DOI":"10.1507\/endocrj.EJ17-0415"},{"key":"3","doi-asserted-by":"crossref","unstructured":"3 O\u2019Hearn M, Lara-Castor L, Cudhea F, Miller V, Reedy J, et al. (2023) Incident type 2 diabetes attributable to suboptimal diet in 184 countries. Nat Med 29: 982\u2013995.","DOI":"10.1038\/s41591-023-02278-8"},{"key":"4","unstructured":"4 Sami W, Ansari T, Butt NS, Hamid MRA (2017) Effect of diet on type 2 diabetes mellitus: a review. Int J Health Sci (Qassim) 11: 65\u201371."},{"key":"5","doi-asserted-by":"crossref","unstructured":"5 Bray GA, Heisel WE, Afshin A, Jensen MD, Dietz WH, et al. (2018) The science of obesity management: an endocrine society scientific statement. Endocr Rev 39: 79\u2013132.","DOI":"10.1210\/er.2017-00253"},{"key":"6","doi-asserted-by":"crossref","unstructured":"6 Wilding JPH, Batterham RL, Calanna S, Davies M, Van Gaal LF, et al. (2021) Once-weekly semaglutide in adults with overweight or obesity. N Engl J Med 384: 989\u20131002.","DOI":"10.1056\/NEJMoa2032183"},{"key":"7","doi-asserted-by":"crossref","unstructured":"7 Blundell J, Finlayson G, Axelsen M, Flint A, Gibbons C, et al. (2017) Effects of once-weekly semaglutide on appetite, energy intake, control of eating, food preference and body weight in subjects with obesity. Diabetes Obes Metab 19: 1242\u20131251.","DOI":"10.1111\/dom.12932"},{"key":"8","doi-asserted-by":"crossref","unstructured":"8 Gibbons C, Blundell J, Tetens Hoff S, Dahl K, Bauer R, et al. (2021) Effects of oral semaglutide on energy intake, food preference, appetite, control of eating and body weight in subjects with type 2 diabetes. Diabetes Obes Metab 23: 581\u2013588.","DOI":"10.1111\/dom.14255"},{"key":"9","doi-asserted-by":"publisher","unstructured":"9 Nagai N, Fujishima Y, Tokuzawa C, Takayanagi S, Yamamoto M, et al. (2024) Food preference assessed by the newly developed nutrition-based japan food preference questionnaire and its association with dietary intake in abdominal-obese subjects. Nutrients 16: 4252.","DOI":"10.3390\/nu16234252"},{"key":"10","doi-asserted-by":"publisher","unstructured":"10 Ryo M, Maeda K, Onda T, Katashima M, Okumiya A, et al. (2005) A new simple method for the measurement of visceral fat accumulation by bioelectrical impedance. Diabetes Care 28: 451\u2013453.","DOI":"10.2337\/diacare.28.2.451"},{"key":"11","doi-asserted-by":"crossref","unstructured":"11 Malavolti M, Mussi C, Poli M, Fantuzzi AL, Salvioli G, et al. (2003) Cross-calibration of eight-polar bioelectrical impedance analysis <i>versus<\/i> dual-energy X-ray absorptiometry for the assessment of total and appendicular body composition in healthy subjects aged 21\u201382 years. Ann Hum Biol 30: 380\u2013391.","DOI":"10.1080\/0301446031000095211"},{"key":"12","doi-asserted-by":"crossref","unstructured":"12 Ogawa W, Hirota Y, Miyazaki S, Nakamura T, Ogawa Y, et al. (2024) Definition, criteria, and core concepts of guidelines for the management of obesity disease in Japan. Endocr J 71: 223\u2013231.","DOI":"10.1507\/endocrj.EJ23-0593"},{"key":"13","doi-asserted-by":"crossref","unstructured":"13 Fujii K, Fujishima Y, Kimura Y, Hara T, Nagao H, et al. (2025) Large-scale web-based survey on eating behaviour in the Japanese general population using a dietary behaviour questionnaire. Diabetes Obes Metab 27: 5737\u20135747.","DOI":"10.1111\/dom.16626"},{"key":"14","doi-asserted-by":"crossref","unstructured":"14 Sorli C, Harashima SI, Tsoukas GM, Unger J, Karsb\u00f8l JD, et al. (2017) Efficacy and safety of once-weekly semaglutide monotherapy <i>versus<\/i> placebo in patients with type 2 diabetes (SUSTAIN 1): a double-blind, randomised, placebo-controlled, parallel-group, multinational, multicentre phase 3a trial. Lancet Diabetes Endocrinol 5: 251\u2013260.","DOI":"10.1016\/S2213-8587(17)30013-X"},{"key":"15","doi-asserted-by":"publisher","unstructured":"15 Aroda VR, Rosenstock J, Terauchi Y, Altuntas Y, Lalic NM, et al. (2019) PIONEER 1: randomized clinical trial of the efficacy and safety of oral semaglutide monotherapy in comparison with placebo in patients with type 2 diabetes. Diabetes Care 42: 1724\u20131732.","DOI":"10.2337\/dc19-0749"},{"key":"16","doi-asserted-by":"crossref","unstructured":"16 Bikou A, Dermiki-Gkana F, Penteris M, Constantinides TK, Kontogiorgis C (2024) A systematic review of the effect of semaglutide on lean mass: insights from clinical trials. Expert Opin Pharmacother 25: 611\u2013619.","DOI":"10.1080\/14656566.2024.2343092"},{"key":"17","doi-asserted-by":"crossref","unstructured":"17 Fujishima Y, Maeda N, Inoue K, Kashine S, Nishizawa H, et al. (2012) Efficacy of liraglutide, a glucagon-like peptide-1 (GLP-1) analogue, on body weight, eating behavior, and glycemic control, in Japanese obese type 2 diabetes. Cardiovasc Diabetol 11: 107.","DOI":"10.1186\/1475-2840-11-107"},{"key":"18","doi-asserted-by":"publisher","unstructured":"18 Masaki T, Ozeki Y, Yoshida Y, Okamoto M, Miyamoto S, et al. (2022) Glucagon-like peptide-1 receptor agonist semaglutide improves eating behavior and glycemic control in japanese obese type 2 diabetic patients. Metabolites 12: 147.","DOI":"10.3390\/metabo12020147"},{"key":"19","doi-asserted-by":"crossref","unstructured":"19 Jalleh RJ, Plummer MP, Marathe CS, Umapathysivam MM, Quast DR, et al. (2024) Clinical consequences of delayed gastric emptying with GLP-1 receptor agonists and tirzepatide. J Clin Endocrinol Metab 110: 1\u201315.","DOI":"10.1210\/clinem\/dgae719"},{"key":"20","doi-asserted-by":"crossref","unstructured":"20 Williams KW, Elmquist JK (2012) From neuroanatomy to behavior: central integration of peripheral signals regulating feeding behavior. Nat Neurosci 15: 1350\u20131355.","DOI":"10.1038\/nn.3217"},{"key":"21","doi-asserted-by":"crossref","first-page":"e133429","DOI":"10.1172\/jci.insight.133429","volume":"5","author":"S Gabery","year":"2020","unstructured":"21 Gabery S, Salinas CG, Paulsen SJ, Ahnfelt-R\u00f8nne J, Alanentalo T, et al. (2020) Semaglutide lowers body weight in rodents <i>via<\/i> distributed neural pathways. JCI Insight 5: e133429.","journal-title":"JCI Insight","ISSN":"https:\/\/id.crossref.org\/issn\/2379-3708","issn-type":"print"},{"key":"22","doi-asserted-by":"publisher","unstructured":"22 Kim KS, Park JS, Hwang E, Park MJ, Shin HY, et al. (2024) GLP-1 increases preingestive satiation <i>via<\/i> hypothalamic circuits in mice and humans. Science 385: 438\u2013446.","DOI":"10.1126\/science.adj2537"},{"key":"23","doi-asserted-by":"publisher","unstructured":"23 Thanopoulou AC, Karamanos BG, Angelico FV, Assaad-Khalil SH, Barbato AF, et al. (2003) Dietary fat intake as risk factor for the development of diabetes: multinational, multicenter study of the Mediterranean Group for the Study of Diabetes (MGSD). Diabetes Care 26: 302\u2013307.","DOI":"10.2337\/diacare.26.2.302"},{"key":"24","doi-asserted-by":"crossref","unstructured":"24 Tanasescu M, Cho E, Manson JE, Hu FB (2004) Dietary fat and cholesterol and the risk of cardiovascular disease among women with type 2 diabetes. Am J Clin Nutr 79: 999\u20131005.","DOI":"10.1093\/ajcn\/79.6.999"},{"key":"25","doi-asserted-by":"crossref","unstructured":"25 Marso SP, Bain SC, Consoli A, Eliaschewitz FG, J\u00f3dar E, et al. (2016) Semaglutide and cardiovascular outcomes in patients with type 2 diabetes. N Engl J Med 375: 1834\u20131844.","DOI":"10.1056\/NEJMoa1607141"},{"key":"26","doi-asserted-by":"crossref","unstructured":"26 Husain M, Bain SC, Jeppesen OK, Lingvay I, S\u00f8rrig R, et al. (2020) Semaglutide (SUSTAIN and PIONEER) reduces cardiovascular events in type 2 diabetes across varying cardiovascular risk. Diabetes Obes Metab 22: 442\u2013451.","DOI":"10.1111\/dom.13955"},{"key":"27","doi-asserted-by":"crossref","unstructured":"27 Friedrichsen M, Breitschaft A, Tadayon S, Wizert A, Skovgaard D (2021) The effect of semaglutide 2.4 mg once weekly on energy intake, appetite, control of eating, and gastric emptying in adults with obesity. Diabetes Obes Metab 23: 754\u2013762.","DOI":"10.1111\/dom.14280"},{"key":"28","doi-asserted-by":"crossref","unstructured":"28 Hironaka J, Ushigome E, Kondo Y, Hashimoto Y, Osaka T, et al. (2025) Changes in food preferences after oral semaglutide administration in Japanese patients with type 2 diabetes: KAMOGAWA-DM cohort. Diab Vasc Dis Res 22: 14791641251318309.","DOI":"10.1177\/14791641251318309"},{"key":"29","doi-asserted-by":"crossref","unstructured":"29 Peters CT, Choi YH, Brubaker PL, Anderson GH (2001) A glucagon-like peptide-1 receptor agonist and an antagonist modify macronutrient selection by rats. J Nutr 131: 2164\u20132170.","DOI":"10.1093\/jn\/131.8.2164"},{"key":"30","doi-asserted-by":"publisher","unstructured":"30 McCarthy D, Berg A (2021) Weight Loss Strategies and the Risk of Skeletal Muscle Mass Loss. Nutrients 13: 2473.","DOI":"10.3390\/nu13072473"},{"key":"31","doi-asserted-by":"crossref","unstructured":"31 InterAct Consortium (2015) Dietary fibre and incidence of type 2 diabetes in eight European countries: the EPIC-InterAct Study and a meta-analysis of prospective studies. Diabetologia 58: 1394\u20131408.","DOI":"10.1007\/s00125-015-3585-9"},{"key":"32","doi-asserted-by":"crossref","unstructured":"32 Weickert MO, Pfeiffer AFH (2018) Impact of dietary fiber consumption on insulin resistance and the prevention of type 2 diabetes. J Nutr 148: 7\u201312.","DOI":"10.1093\/jn\/nxx008"},{"key":"33","doi-asserted-by":"crossref","unstructured":"33 West J, Li M, Wong S, Le GH, Teopiz KM, et al. (2025) Are Glucagon-Like Peptide-1 (GLP-1) receptor agonists Central Nervous System (CNS) penetrant: a narrative review. Neurol Ther 14: 1157\u20131166.","DOI":"10.1007\/s40120-025-00724-y"},{"key":"34","doi-asserted-by":"crossref","unstructured":"34 Zhu Z, Gong R, Rodriguez V, Quach KT, Chen X, et al. (2025) Hedonic eating is controlled by dopamine neurons that oppose GLP-1R satiety. Science 387: eadt0773.","DOI":"10.1126\/science.adt0773"},{"key":"35","doi-asserted-by":"crossref","unstructured":"35 Brindisi MC, Brondel L, Meillon S, Barthet S, Grall S, et al. (2019) Proof of concept: Effect of GLP-1 agonist on food hedonic responses and taste sensitivity in poor controlled type 2 diabetic patients. Diabetes Metab Syndr 13: 2489\u20132494.","DOI":"10.1016\/j.dsx.2019.06.021"},{"key":"36","doi-asserted-by":"crossref","unstructured":"36 Edwin Thanarajah S, DiFeliceantonio AG, Albus K, Kuzmanovic B, Rigoux L, et al. (2023) Habitual daily intake of a sweet and fatty snack modulates reward processing in humans. Cell Metab 35: 571\u2013584.e576.","DOI":"10.1016\/j.cmet.2023.02.015"},{"key":"37","doi-asserted-by":"crossref","unstructured":"37 McDougle M, de Araujo A, Singh A, Yang M, Braga I, et al. (2024) Separate gut-brain circuits for fat and sugar reinforcement combine to promote overeating. Cell Metab 36: 393\u2013407.e397.","DOI":"10.1016\/j.cmet.2023.12.014"},{"key":"38","doi-asserted-by":"crossref","unstructured":"38 Ka\u0142as M, St\u0119pniewska E, Gniedziejko M, Leszczy\u0144ski-Czeczatka J, Siemi\u0144ski M (2025) Glucagon-like peptide-1 receptor agonists in the context of eating disorders: a promising therapeutic option or a double-edged sword? J Clin Med 14: 3122.","DOI":"10.3390\/jcm14093122"},{"key":"39","doi-asserted-by":"crossref","unstructured":"39 Murayama T, Hosojima M, Kabasawa H, Tanaka T, Kitamura N, et al. (2024) Changes in daily intake of nutrients and foods including confectionery after the initiation of empagliflozin in Japanese patients with type 2 diabetes: a pilot study. BMC Nutr 10: 95.","DOI":"10.1186\/s40795-024-00902-5"}],"container-title":["Endocrine Journal"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.jstage.jst.go.jp\/article\/endocrj\/73\/5\/73_EJ25-0402\/_pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,5,9]],"date-time":"2026-05-09T03:22:24Z","timestamp":1778296944000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.jstage.jst.go.jp\/article\/endocrj\/73\/5\/73_EJ25-0402\/_article"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026]]},"references-count":39,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2026]]}},"URL":"https:\/\/doi.org\/10.1507\/endocrj.ej25-0402","relation":{},"ISSN":["0918-8959","1348-4540"],"issn-type":[{"value":"0918-8959","type":"print"},{"value":"1348-4540","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026]]},"article-number":"EJ25-0402"}}